维持性血液透析患者肾性贫血应用左卡尼汀联合促红素的治疗效果

To Maintain the Therapeutic Effects of Levocarnitine Combined With Erythropoietin in the Treatment of Hemodialysis Patients With Renal Anemia

目的研究对维持性血液透析患者肾性贫血的病例应用左卡尼汀与促红素相联合的方式进行治疗的临床效果。方法选取2014年1月—2017年1月来我院接收治疗的维持性血液透析的肾性贫血患者32例作为研究对象。采用随机数字法将其分为观察组与对照组,每组各16例。对照组采用正常剂量的促红细胞生成素(EPO)来进行治疗,观察组患者在此基础上联合左卡尼汀进行治疗。结果两组患者在接受6个月的治疗后,红细胞比容以及血红蛋白等指标对比,差异均具有统计学意义(P<0.05)。结论对维持性血液透析肾性贫血的患者采用左卡尼汀与促红素联合治疗,效果显著。

Objective To study the clinical application of levocarnitine and erythropoietin in hemodialysis patients with renal anemia is a combination of the clinical effect of treatment. Methods From January 2014 to January 2017, 32 cases of patients with renal anemia who received treatment in our hospital were selected as the subjects. The patients were randomly divided into observation group and control group, 16 cases in each group. The control group used normal dose hormone erythropoietin（EPO） for treatment, patients in the observation group on the basis of combined L-carnitine treatment. Results After 6 months of treatment, the patients in the two groups were treated, hematocrit and hemoglobin contrast, the difference was statistically significant（P〈0.05）. Conclusion Patientswith maintenance hemodialysis renal anemia with levocarnitine and erythropoietin combined treatment effect.